{"id":9933,"date":"2026-01-13T12:02:53","date_gmt":"2026-01-13T11:02:53","guid":{"rendered":"https:\/\/www.positrigo.com\/?p=9933"},"modified":"2026-02-19T11:00:31","modified_gmt":"2026-02-19T10:00:31","slug":"positrigo-joins-the-access-ad-initiative","status":"publish","type":"post","link":"https:\/\/www.positrigo.com\/en-gb\/positrigo-joins-the-access-ad-initiative\/","title":{"rendered":"Positrigo joins the ACCESS-AD Initiative"},"content":{"rendered":"\n\n\n\n\n\n<section id=\"res-header-image-block_619ca098a7574\" class=\"res-block res-header-image alignfull\">\n  <div class=\"res-header-img-outside mb-4\" data-aos=\"res-fadeIn\">\n\t<div class=\"res-header-height\">\n\t\t\n\t\n\t  <style> \n\t\t  @media only screen and (min-width: 970px) {\n\t\t\t #res-header-image-block_619ca098a7574.res-header-image .layout-1.header-img-height { height: 70vh;}  \n\t\t\t #res-header-image-block_619ca098a7574.res-header-image .layout-1 .res-header-image-vertical-center { top: 72%;} \n\t\t\t   \n\t\t  }\n\t\t  @media only screen and (max-width: 970px) {  \n\t\t\t#res-header-image-block_619ca098a7574.res-header-image .layout-1.header-img-height { height: 55vh;} \n\t\t\t#res-header-image-block_619ca098a7574.res-header-image .layout-1 .res-header-image-vertical-center { top: 55%;} \n\t\t\t    \n\t\t\t  \t\t  }\n\t\t   \n\t\t\t  @media only screen and (min-width: 1280px) {\n\t\t\t\t\t\t\t\t#res-header-image-block_619ca098a7574.res-header-image .layout-1 h1 {font-size: 200%; line-height: 105%;}\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t\t  }   \n\t\t \t  <\/style> \n\t\t\n\t  <div class=\"layout-1 jarallax header-img-height\" data-speed=\"0.6\" style=\"background-color: #fff;\">\n\t\t  \n\t\t\t\t<div class=\"res-header-image-vertical-center\">\n\t\t\t\t\t<div class=\"container-fluid\">\n\t\t\t\t\t\t\n\t\t\t\t\t\t<div class=\"sloganBox\">\n                           <div class=\"row\">\n                             <div class=\"col col-md-10 text-left\">\n\t\t\t\t\t\t\t\t <div class=\"sloganbox-background text-white\" data-aos=\"res-fadeIn\">\n\t\t\t\t\t\t\t\t \n                                \t\n\t\t\t\t\t\t\t\t \n                                  \n\t\t\t\t\t\t\t\t \t<h2>Positrigo joins ACCESS-AD Initiative<\/h2>\n                                \t\t\t\t\t\t\t\t \n                                \t\n\t\t\t\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t\t\t \t\t\t\t\t\t\t\t \t\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t                 <\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\n                                            <img decoding=\"async\" class=\"jarallax-img img-fluid\" src=\"https:\/\/www.positrigo.com\/wp-content\/uploads\/2026\/01\/Brain-1-1920x1080.jpg\"  style=\"opacity: 0.8;\" alt=\"\"\/>\n                    \t\t  \n\t\t\t\t\n\t\t   <\/div>\n\t\t\t \n\t \n\n\n\t\t<\/div>\n\t<\/div>\n<\/section>\t\n\n\n\n<section id=\"res-txt-block_619ca0bca7575\" class=\"res-block res-txt  p-no\" style=\"background: transparent;\">\n  <div class=\"inner-container container-off\" data-aos=\"res-fadeIn\">\n \n\t\t  \n\t\t \t  \n      \n      <div class=\"layout-1 txt-section\">\n\t\t<div class=\"row\">\t\n\t\t\t\n\t\t\n\t\t\t<div class=\"col-md-12 var-1spalten \">\n\t\t\t\t\n\t\t\t\t<div class=\"txt-title-field\">\n\t\n\t\t\t\t\t\n\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t \n\t\t\t\t\t<\/div> \n\t\t\t\t\t\n\t\t\t\t\t<div class=\"txt-textfield postContent pt-md-0\">\n\t\t\t\t\t\t\t\t\t\t  <p>January 13, 2026<\/p>\n<h3><strong style=\"font-size: 22.4px;\">Positrigo joins the ACCESS-AD Initiative<\/strong><\/h3>\n<p><strong><em>ACCESS-AD launches to advance Alzheimer\u2019s disease diagnosis and treatment across Europe<\/em><\/strong><\/p>\n<p>A new European initiative, <a href=\"https:\/\/www.access-ad.org\/\">ACCESS-AD<\/a>, was officially launched on Tuesday 13 January. It\u2019s goal: to help people with Alzheimer\u2019s disease get diagnosed, treated and supported in a more timely and equitable way, wherever they live in Europe.<\/p>\n<p>ACCESS-AD is a five-year program, co-led by Amsterdam UMC, Siemens Healthineers, King\u2019s College London and Gates Ventures, receiving funding under the auspices of the European Union\u2019s Innovative Health Initiative. With an initial budget of over \u20ac37 million, comprising ~\u20ac20 million from the EU and ~\u20ac17 million from industry partners, ACCESS-AD brings together 30 organizations including universities, hospitals, patient organizations, SMEs, medical device manufacturers and pharmaceutical companies.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t<\/div> \n\t\t\t\t\t\n\t\t\t\t\t <div class=\"txt-textfield-btns pt-2 \">\n\t\t\t\t\t\t  \n\t\t\t\t\t<\/div> \n\t\t\t\t\n\t\t\t\t\t\t\n\t\n\t\t\t\t<\/div>\n\n\t\t \n\t\t\t\n\t\t\t\n\t\t\t\n\n\t\t\t\t\t\n\t\t <\/div> \t\n\t\t<\/div>\n\t \n\t  \n \n \n\t<\/div>\n<\/section>\n\n\n\n\n\n<section id=\"res-text-bild-block_6937f905cba5d\" class=\"res-block res-text-bild layout01 p-no\" style=\"background: transparent;\">\n  <div class=\"inner-container container-off\" data-aos=\"res-fadeIn\">\n\n\t\t\t  <style>\n\t\t\t @media only screen and (min-width: 970px) {\n\t\t\t  #res-text-bild-block_6937f905cba5d.res-text-bild .layout-1 .txt-imagebox.offset-md-1 {margin-left: 3%;}\n\t\t\t  #res-text-bild-block_6937f905cba5d.res-text-bild .layout-1 .txt-box.offset-md-1 {margin-left: 3%;}\n\t\t\t}\n\t\t\t \n\t\t  <\/style>\n\n\n        <div class=\"layout-1 row \">\n\t\t\t<div class=\"col-md-7 txt-box \">\n\n\n\t\t\t\n\t\t\t\t\t\t\t\t\n\t\t\t\t\n\n\t\t\t\t <div class=\"txt-text postContent pt-2 pt-md-2\">\n\t\t\t\t\t\t\t\t\t\t  <p><em><strong>\u201cPositrigo is joining this initiative to address one of the most critical bottlenecks in Alzheimer\u2019s diagnostics: accessibility. By providing the NeuroLF system, we aim to demonstrate that brain PET imaging can be scaled to serve the broader population &#8211; not just a select few. Our focus is on validating accessible imaging solutions that integrate seamlessly into real-world clinical workflows, turning the vision of \u201cimaging everyone\u201d into a practical clinical reality.\u201d<\/strong> <\/em><\/p>\n<p><strong>Dr. Max Ahnen<\/strong>, Co-Founder at Chief Science Officer at Positrigo<\/p>\n\t\t\t\t\t\n\t\t\t\t\t \n\t\t\t\t\t\n\t\t\t\t<\/div>\n\n\n\t\t\t<\/div>\n\n\t\t\t<div class=\"col-md mb-2 mt-md-1 txt-imagebox offset-md-1\">\n\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"440\" height=\"270\" src=\"https:\/\/www.positrigo.com\/wp-content\/uploads\/2024\/09\/Max-440x270.jpg\" class=\"img-fluid w-100 txt-img\" alt=\"\" \/>\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\n\n\t\n\t<\/div>\n<\/section>\n\n\n\n\n\n<section id=\"res-txt-block_6937f942cba5e\" class=\"res-block res-txt layout01 p-no\" style=\"background: transparent;\">\n  <div class=\"inner-container container-off\" data-aos=\"res-fadeIn\">\n \n\t\t  \n\t\t \t  \n      \n      <div class=\"layout-1 txt-section\">\n\t\t<div class=\"row\">\t\n\t\t\t\n\t\t\n\t\t\t<div class=\"col-md-12 var-1spalten text-left\">\n\t\t\t\t\n\t\t\t\t<div class=\"txt-title-field\">\n\t\n\t\t\t\t\t\n\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t \n\t\t\t\t\t<\/div> \n\t\t\t\t\t\n\t\t\t\t\t<div class=\"txt-textfield postContent pt-md-2\">\n\t\t\t\t\t\t\t\t\t\t  <p>The project starts at a critical time for the Alzheimer\u2019s disease community. In 2025, the first medicines designed to slow the course of the disease were approved in Europe. While this is an important breakthrough, many health systems are struggling to put new science into everyday practice. Long waiting lists, shortages of specialists and limited access to advanced tests mean that many people are still diagnosed and treated too late. At the same time, the number of people living with dementia continues to rise and is expected to exceed 19 million in Europe by 2050.<\/p>\n<p>ACCESS-AD aims to tackle these challenges to help healthcare systems respond more quickly, efficiently and equitably. The project is developing a practical framework for diagnosis and treatment that combines brain scans, simple blood tests, digital tools and artificial intelligence to support doctors in making faster and more accurate decisions. The goal is to bring high-quality diagnosis and follow-up closer to patients, including outside major specialist centres.<\/p>\n<p>The initiative covers the full patient journey: spotting early signs of disease, confirming a diagnosis, choosing the most suitable treatment, and monitoring patients safely over time. Alongside new medicines for Alzheimer\u2019s disease, ACCESS-AD will also explore lifestyle interventions and nutritional approaches that may support brain health. Real-world data from patients in different countries will play a central role, helping decision-makers and healthcare providers understand what works best in everyday settings. Patients and carers are closely involved to ensure that care remains person-centred.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t<\/div> \n\t\t\t\t\t\n\t\t\t\t\t <div class=\"txt-textfield-btns pt-2 \">\n\t\t\t\t\t\t  \n\t\t\t\t\t<\/div> \n\t\t\t\t\n\t\t\t\t\t\t\n\t\n\t\t\t\t<\/div>\n\n\t\t \n\t\t\t\n\t\t\t\n\t\t\t\n\n\t\t\t\t\t\n\t\t <\/div> \t\n\t\t<\/div>\n\t \n\t  \n \n \n\t<\/div>\n<\/section>\n\n\n\n\n\n<section id=\"res-text-bild-block_69665fd8e3079\" class=\"res-block res-text-bild layout01 p-no\" style=\"background: transparent;\">\n  <div class=\"inner-container container-off\" data-aos=\"res-fadeIn\">\n\n\t\t\t  <style>\n\t\t\t @media only screen and (min-width: 970px) {\n\t\t\t  #res-text-bild-block_69665fd8e3079.res-text-bild .layout-1 .txt-imagebox.offset-md-1 {margin-left: 3%;}\n\t\t\t  #res-text-bild-block_69665fd8e3079.res-text-bild .layout-1 .txt-box.offset-md-1 {margin-left: 3%;}\n\t\t\t}\n\t\t\t \n\t\t  <\/style>\n\n\n        <div class=\"layout-1 row \">\n\t\t\t<div class=\"col-md-7 txt-box \">\n\n\n\t\t\t\n\t\t\t\t\t\t\t\t\n\t\t\t\t\n\n\t\t\t\t <div class=\"txt-text postContent pt-2 pt-md-2\">\n\t\t\t\t\t\t\t\t\t\t  <p><strong><em>\u201cOur vision is simple but ambitious: to make personalized care a reality for every patient with AD, regardless of where they live. <\/em><em>ACCESS-AD brings together the clinical, scientific and societal stakeholders needed to turn innovation into everyday practice across Europe.\u201d<\/em><\/strong><\/p>\n<p><em><strong>Professor Frederik Barkhof<\/strong><\/em> from Amsterdam UMC and Clinical Lead of ACCESS-AD<\/p>\n\t\t\t\t\t\n\t\t\t\t\t \n\t\t\t\t\t\n\t\t\t\t<\/div>\n\n\n\t\t\t<\/div>\n\n\t\t\t<div class=\"col-md mb-2 mt-md-1 txt-imagebox offset-md-1\">\n\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"440\" height=\"270\" src=\"https:\/\/www.positrigo.com\/wp-content\/uploads\/2026\/01\/Barkhoff-440x270.jpg\" class=\"img-fluid w-100 txt-img\" alt=\"\" \/>\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\n\n\t\n\t<\/div>\n<\/section>\n\n\n\n\n\n<section id=\"res-txt-block_69665ff8e307a\" class=\"res-block res-txt layout01 p-no\" style=\"background: transparent;\">\n  <div class=\"inner-container container-off\" data-aos=\"res-fadeIn\">\n \n\t\t  \n\t\t \t  \n      \n      <div class=\"layout-1 txt-section\">\n\t\t<div class=\"row\">\t\n\t\t\t\n\t\t\n\t\t\t<div class=\"col-md-12 var-1spalten text-left\">\n\t\t\t\t\n\t\t\t\t<div class=\"txt-title-field\">\n\t\n\t\t\t\t\t\n\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t \n\t\t\t\t\t<\/div> \n\t\t\t\t\t\n\t\t\t\t\t<div class=\"txt-textfield postContent pt-md-2\">\n\t\t\t\t\t\t\t\t\t\t  <p><strong>About ACCESS-AD<\/strong><\/p>\n<p>ACCESS-AD receives funding under the auspices of the Innovative Health Initiative Joint Undertaking (IHI JU). The ACCESS-AD program has an initial budget of over \u20ac37 million, comprising ca. \u20ac20 million from the EU and ca. \u20ac17 million from the industry partners. The budget is distributed across the following 30 partners:<\/p>\n<p><a href=\"https:\/\/www.alzheimercentrum.nl\/\">Stichting Amsterdam UMC<\/a>, <a href=\"https:\/\/www.siemens-healthineers.com\/\">Siemens Healthineers AG<\/a>, <a href=\"https:\/\/www.kcl.ac.uk\/\">King\u2019s College London<\/a>, <a href=\"https:\/\/www.linkedin.com\/company\/gatesventures\">Gates Ventures LLC<\/a>, <a href=\"https:\/\/www.alzheimer-europe.org\/\">Alzheimer Europe<\/a>, <a href=\"https:\/\/www.anavex.com\/\">Anavex Germany GmbH<\/a>, <a href=\"https:\/\/www.amsterdamumc.org\/en\/research-support\/amsterdamumcresearchbv.htm\">Amsterdam UMC Research BV<\/a>, <a href=\"https:\/\/www.dzne.de\/\">Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen EV<\/a>, <a href=\"https:\/\/www.eisai.com\/index.html\">Eisai Limited<\/a>, <a href=\"https:\/\/www.certh.gr\/\">Ethniko Kentro Erevnas Kai Technologikis Anaptyxis<\/a>, <a href=\"https:\/\/www.fnmotol.cz\/\">Fakultni Nemocnice v Motole<\/a>, <a href=\"https:\/\/www.fraunhofer.de\/en.html\">Fraunhofer Gesellschaft zur F\u00f6rderung der Angewandten Forschung EG<\/a>, <a href=\"https:\/\/www.clinicbarcelona.org\/ca\/idibaps\/sobre-nosaltres\">Fundacio de Recerca Clinic Barcelona \u2013 Institut d\u2019Investigacions biomediques August pi Sunyer<\/a>, <a href=\"https:\/\/www.helse-stavanger.no\/en\/english\/\">Helse Stavanger HF<\/a>, <a href=\"https:\/\/www.clinicbarcelona.org\/en\">Hospital Clinic de Barcelona<\/a>, <a href=\"https:\/\/www.inradnetwork.org\/\">InRAD &#8211; Stichting International Registry for Alzheimer\u2019s Disease and other Dementia<\/a>,\u00a0<a href=\"https:\/\/www.inradnetwork.org\/\">Karolinska Institutet<\/a>, <a href=\"https:\/\/www.lmu-klinikum.de\/\">Klinikum der Ludwig-Maximilians Universit\u00e4t M\u00fcnchen<\/a>, <a href=\"https:\/\/www.lmu.de\/en\/\">Ludwig-Maximilians Universit\u00e4t M\u00fcnchen<\/a>, <a href=\"https:\/\/corporate.muhdo.com\/\">Muhdo Health Ltd<\/a>, <a href=\"https:\/\/www.nice.org.uk\/\">National Institute for Health and Care Excellence<\/a>, <a href=\"https:\/\/neotiv.com\/\">Neotiv GmbH<\/a>, <a href=\"https:\/\/www.neurimmune.com\/\">Neurimmune SubOne AG<\/a>, <a href=\"https:\/\/pshyvinvointialue.fi\/web\/en\">Pohjois-Savon Hyvinvointialue<\/a>, <a href=\"https:\/\/www.positrigo.com\/\">Positrigo AG<\/a>, <a href=\"https:\/\/www.regionstockholm.se\/sprak\/english\/\">Region Stockholm<\/a>, <a href=\"https:\/\/www.nestle.ch\/fr\">Societ\u00e9 de Produits Nestl\u00e9 SA<\/a>, <a href=\"https:\/\/www.unav.edu\/\">Universidad de Navarra<\/a>, <a href=\"https:\/\/www.uk-erlangen.de\/\">Universit\u00e4tsklinikum Erlangen<\/a>, <a href=\"https:\/\/www.ucl.ac.uk\/\">University College London<\/a>, <a href=\"https:\/\/le.ac.uk\/\">University of Leicester<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong><em>Acknowledgement<\/em><\/strong><\/p>\n<p><em>This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement N<sup>o<\/sup> 101253010. The JU receives support from the European Union\u2019s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa B\u00edo, MedTech Europe, and Vaccines Europe, and Anavex, Muhdo and Neurimmune. <\/em><\/p>\n<p><strong><em>Disclaimer<\/em><\/strong><\/p>\n<p><em>ACCESS-AD is funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. None of the aforementioned parties can be held responsible for them.<\/em><\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t<\/div> \n\t\t\t\t\t\n\t\t\t\t\t <div class=\"txt-textfield-btns pt-2 \">\n\t\t\t\t\t\t  \n\t\t\t\t\t<\/div> \n\t\t\t\t\n\t\t\t\t\t\t\n\t\n\t\t\t\t<\/div>\n\n\t\t \n\t\t\t\n\t\t\t\n\t\t\t\n\n\t\t\t\t\t\n\t\t <\/div> \t\n\t\t<\/div>\n\t \n\t  \n \n \n\t<\/div>\n<\/section>\n\n","protected":false},"excerpt":{"rendered":"<p>January 13, 2026<br \/>\nACCESS-AD launches to advance Alzheimer\u2019s disease diagnosis and treatment across Europe<\/p>\n","protected":false},"author":4,"featured_media":9992,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[1,18],"tags":[],"class_list":["post-9933","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/posts\/9933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/comments?post=9933"}],"version-history":[{"count":14,"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/posts\/9933\/revisions"}],"predecessor-version":[{"id":10413,"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/posts\/9933\/revisions\/10413"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/media\/9992"}],"wp:attachment":[{"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/media?parent=9933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/categories?post=9933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.positrigo.com\/en-gb\/wp-json\/wp\/v2\/tags?post=9933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}